Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Brentuximab vedotin plus DHAP as effective salvage therapy in CD30+ peripheral T-cell lymphoma: A retrospective multicenter study

View Full Paper
Ask AI
Bookmark
Share

Authors

TBTill BraunBTBastian von Tresckow

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows improved efficacy of brentuximab vedotin with DHAP in R/R T-NHL, indicating safer treatment options.

Key Points

  • Evaluate the efficacy and tolerability of brentuximab vedotin in combination with platinum-based salvage therapies for R/R T-NHL.
  • Retrospective multicenter study
  • Analysis of data from national T-NHL registry
  • Focused on patients treated with BV-DHAP or BV-ICE between 2015 and 2025
  • Total of 26 patients included in the cohort
  • Best overall response rate (ORR) was 53.9% for the entire cohort
  • BV-DHAP subgroup showed an ORR of 83.3%
  • Manageable toxicity with grade 3/4 hematologic adverse events observed in 85.7% of patients
  • Febrile neutropenia reported in 61.9% of patients

Cite This Study

Braun et al. (2025) studied this question.

synapsesocial.com/papers/69362f694fa91c937236deb4https://doi.org/10.1182/blood-2025-5425
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Safety and effectiveness of brentuximab vedotin in Chinese patients with CD30-positive lymphomas: A multicenter real-world analysis2025
  2. 2Randomized Phase II Study of Brentuximab‐Vedotin With High‐Dose Chemotherapy in CD30 Positive Lymphoma2025 · 1 citations
  3. 3Brentuximab Vedotin addition to Gemcitabine in Relapsed or Refractory Peripheral T-cell Lymphoma: a LYSA Phase II Study2025 · 5 citations
  4. 4Brentuximab Vedotin and Chemotherapy in Relapsed/Refractory Hodgkin Lymphoma: a Propensity Score Matched Analysis2024 · 5 citations
  5. 5Real-world, multicenter study of brentuximab vedotin-based regimens in Chinese patients with relapsed/refractory Hodgkin lymphoma2025